Oct2_NN
transactivation_NN
from_IN
a_DT
remote_JJ
enhancer_NN
position_NN
requires_VBZ
a_DT
B-cell-restricted_JJ
activity_NN
._.

Previous_JJ
cotransfection_NN
experiments_NNS
had_VBD
demonstrated_VBN
that_IN
ectopic_JJ
expression_NN
of_IN
the_DT
lymphocyte-specific_JJ
transcription_NN
factor_NN
Oct2_NN
could_MD
efficiently_RB
activate_VB
a_DT
promoter_NN
containing_VBG
an_DT
octamer_NN
motif_NN
._.

Oct2_NN
expression_NN
was_VBD
unable_JJ
to_TO
stimulate_VB
a_DT
multimerized_JJ
octamer_NN
enhancer_NN
element_NN
in_IN
HeLa_NN
cells_NNS
,_,
however_RB
._.

We_PRP
have_VBP
tested_VBN
a_DT
variety_NN
of_IN
Oct2_NN
isoforms_NNS
generated_VBN
by_IN
alternative_JJ
splicing_NN
for_IN
the_DT
capability_NN
to_TO
activate_VB
an_DT
octamer_NN
enhancer_NN
in_IN
nonlymphoid_JJ
cells_NNS
and_CC
a_DT
B-cell_NN
line_NN
._.

Our_PRP$
analyses_NNS
show_VBP
that_IN
several_JJ
Oct2_NN
isoforms_NNS
can_MD
stimulate_VB
from_IN
a_DT
remote_JJ
position_NN
but_CC
that_IN
this_DT
stimulation_NN
is_VBZ
restricted_JJ
to_TO
B_NN
cells_NNS
._.

This_DT
result_NN
indicates_VBZ
the_DT
involvement_NN
of_IN
either_CC
a_DT
B-cell-specific_JJ
cofactor_NN
or_CC
a_DT
specific_JJ
modification_NN
of_IN
a_DT
cofactor_NN
or_CC
the_DT
Oct2_NN
protein_NN
in_IN
Oct2-mediated_JJ
enhancer_NN
activation_NN
._.

Mutational_JJ
analyses_NNS
indicate_VBP
that_IN
the_DT
carboxy-terminal_JJ
domain_NN
of_IN
Oct2_NN
is_VBZ
critical_JJ
for_IN
enhancer_NN
activation_NN
._.

Moreover_RB
,_,
this_DT
domain_NN
conferred_VBD
enhancing_VBG
activity_NN
when_WRB
fused_VBN
to_TO
the_DT
Oct1_NN
protein_NN
,_,
which_WDT
by_IN
itself_PRP
was_VBD
unable_JJ
to_TO
stimulate_VB
from_IN
a_DT
remote_JJ
position_NN
._.

The_DT
glutamine-rich_JJ
activation_NN
domain_NN
present_JJ
in_IN
the_DT
amino-terminal_JJ
portion_NN
of_IN
Oct2_NN
and_CC
the_DT
POU_NN
domain_NN
contribute_VBP
only_RB
marginally_RB
to_TO
the_DT
transactivation_NN
function_NN
from_IN
a_DT
distal_JJ
position_NN
._.

